Drug – bio-affecting and body treating compositions – Designated organic active ingredient containing – Having -c- – wherein x is chalcogen – bonded directly to...
Reexamination Certificate
2005-10-04
2005-10-04
Berch, Mark L. (Department: 1624)
Drug, bio-affecting and body treating compositions
Designated organic active ingredient containing
Having -c-, wherein x is chalcogen, bonded directly to...
C544S251000, C544S250000, C544S249000, C546S080000, C546S081000
Reexamination Certificate
active
06951865
ABSTRACT:
The present invention provides a novel compound having an excellent corticotrophin-releasing-factor receptor antagonistic activity. That is, it provides a compound represented by the following formula, a pharmacologically acceptable salt thereof or hydrates thereof.Wherein A, B and D are the same as or different from each other and each represents a group represented by the formula —(CR1R2)m— (wherein R1and R2are the same as or different from each other and each represents a C1-6alkyl group etc.), —NR3— (wherein R3represetns hydrogen etc.) etc.; E and G are the same as or different from each other and each represents a group represented by the formula —(CR6R7)p— (wherein R6and R7are the same as or different from each other and each represents hydrogen etc.; and p represents an integer of 0, 1 or 2); J represents a carbon atom or nitrogen atom, each substituted with C1-6alkyl group optionally substituted with a halogen atom, etc.; K and L are the same as or different from each other and each represents carbon atom or nitrogen atom; M means hydrogen, a halogen atom, an optionally substituted C1-6alkyl group etc.; and the partial structuremeans a single or double bond.
REFERENCES:
patent: 4007189 (1977-02-01), Sato et al.
patent: 5942515 (1999-08-01), Namiki et al.
patent: 347252 (1989-12-01), None
patent: 0 369 145 (1990-05-01), None
patent: 0 611 766 (1994-08-01), None
patent: 0 659 747 (1995-06-01), None
patent: 46-31228 (1971-09-01), None
patent: 2-275882 (1990-11-01), None
patent: 5-255337 (1993-10-01), None
patent: 11-43434 (1999-02-01), None
patent: WO94/13643 (1994-06-01), None
patent: WO94/13661 (1994-06-01), None
patent: WO94/13676 (1994-06-01), None
patent: WO94/13677 (1994-06-01), None
patent: WO94/18644 (1994-08-01), None
patent: WO95/10506 (1995-04-01), None
patent: WO95/34563 (1995-12-01), None
patent: WO97/29109 (1997-08-01), None
patent: WO97/29110 (1997-08-01), None
patent: WO 97/44038 (1997-11-01), None
patent: WO98/08847 (1998-03-01), None
patent: 98/08847 (1998-03-01), None
patent: 98/33799 (1998-08-01), None
patent: WO 98/45295 (1998-10-01), None
Gut 2000, (Suppl ll)47:ii1-ii19.
Chalmers TiPS 17, 166-172 (1996).
Sato et al., J. Med. Chem., vol. 23, No. 8, pp. 927-937 (1980).
Chemical Abstracts, vol. 96, NO. 17, p. 749, abstract No. 142751b.
The Merck Index, Twelfth Edition, Merck & Co., p. 845, Mongraph No. 4957.
Wylie Vale et al., Science, vol. 213, (Sep. 18, 1981), pp. 1394-1397.
Jean Rivier et al., Proc. Natl. Acad. Sci. USA, vol. 80, (Aug. 1983), pp. 4851-4855.
Shigeki Shibahara et al., The EMBO Journal, vol. 2, No. 5, (1983), pp. 775-779.
Atsushi Sasaki et al., Journal of Clinical Endocrinology and Metabolism, vol. 65, No. 1, (1987), pp. 176-182.
Atsushi Sasaki et al., Journal of Clinical Endocrinology and Metabolism, vol. 67, No. 4, (1988), pp. 768-773.
Wendell E. Nicholson et al., Regulatory Peptides, vol. 18, (1987), pp. 173-188.
P. Petrusz et al., Peptides, vol. 5, Suppl. 1, (1984), pp. 71-78.
Derek T. Chalmers et al., The Journal of Neuroscience, vol. 15, No. 10, (Oct. 1995), pp. 6340-6350.
Chen W. Liaw et al., Endocrinology, vol. 137, No. 1, (1996), pp. 72-77.
Olivier Valdenaire et al., Biochimica et Biophysica Acta, vol. 1352, (1997), pp. 129-132.
Wylie Vale et al., Recent Progress in Hormone Research, vol. 39, (1983), pp. 245-270.
Adrian J. Dunn et al., Brain Research Reviews, vol. 15, (1990), pp. 71-100.
Michael J. Owens et al., Pharmacological Reviews, vol. 43, No. 4, (1991), pp. 425-473.
Csaba M. Banki et al., American Journal Psychiatry, vol. 144, No. 7, (Jul. 1987), pp. 873-877.
Frederik C. Raadsheer, PhD et al., American Journal Psychiatry, vol. 152, No. 9, (Sep. 1995), pp. 1372-1376.
Charles B Nemeroff, MD, PhD. et al., Arch. Gen. Psychiatry, vol. 45, (Jun. 1988), pp. 577-579.
Philip W. Gold, M.D. et al., The New England Journal of Medicine, vol. 314, No. 21, (May 22, 1986), pp. 1329-1335.
Margaret Altemus MD et al., Arch. Gen. Psychiatry, vol. 51, (Oct. 1994), pp. 794-803.
J. Douglas Bremner, MD et al., American Journal Psychiatry, vol. 154, No. 5, (May 1997), pp. 624-629.
Phillip Chappell et al., Biological Psychiatry, vol. 39, (1996), pp. 776-783.
Peter P. Roy-Byrne, MD et al., American Journal Psychiatry, vol. 143, No. 7, (Jul. 1986), pp. 896-899.
Hubert Monnikes et al., Brain Research, vol. 574, (1992), pp. 70-76.
Pamela D. Butler et al., The Journal of Neuroscience, vol. 10, No. 1, (Jan. 1990), pp. 176-183.
Mary P. Stenzel-Poore et al., The Journal of Neuroscience, vol. 14, No. 5, (May 1994), pp. 2579-2584.
Michael J. Owens et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 258, No. 1, (1991), pp. 349-356.
Ned H. Kalin et al., Brain Research, vol. 509, (1990), pp. 80-84.
A. Tazi et al., Regulatory Peptides, vol. 18, (1987), pp. 37-42.
Helen A. Baldwin et al., Psychopharmacology, vol. 103, (1991), pp. 227-232.
Dalip J.S. Sirinathsinghji et al., Nature, vol. 305, (Sep. 15, 1983), pp. 232-267.
Jack E. Sherman et al., Pharmacology Biochemistry and Behavior, vol. 26, (1987), pp. 699-703.
Mark K. Lyons et al., Brain Research, vol. 545, (1991), pp. 339-342.
Paul J.L.M. Strijbos et al., Brain Research, vol. 656, (1994), pp. 405-408.
C.L. Ehlers et al., Brain Research, vol. 278, (1983), pp. 332-336.
Csaba M. Banki, MD et al., American Journal Psychiatry, vol. 144, No. 7, (Jul. 1987), pp. 873-877.
P.J. Whitehouse, MD, PhD. et al., Neurology, vol. 37, (Jun. 1987), pp. 905-909.
Errol B. DeSouza et al., Brain Research, vol. 437, (1987), pp. 355-359.
Randy J. Nelson et al., Letters to Nature, vol. 378, (Nov. 23, 1995), pp. 383-386.
Michaela Diamant et al., Neuroendocrinology, vol. 57, (1993), pp. 1071-1081.
M.P. Stenzel-Poore et al., Endocrinology, vol. 130, No. 6, (1992), pp. 3378-3386.
Mari Hotta et al, Journal of Clinical Endocrinology and Metabolism, vol. 62, No. 2, (1986), pp. 319-324.
A.S. Levine et al., Neuropharmacology, vol. 22, No. 3A, (1983), pp. 337-339.
Dean D. Krahn et al., Brain Research Bulletin, vol. 17, (1986), pp. 285-289.
K. Arase et al., Physiology and Behavior, vol. 45, (1989), pp. 565-570.
Paul M. Plotsky et al., Endocrinology, vol. 130, No. 4, (1992), pp. 1931-1941.
Thomas Garrick et al., Regulatory Peptides, vol. 21, (1988), pp. 173-181.
Y. Tache et al., American Journal Physiol., vol. 253, (1987), pp. G241-G245.
E. Barquist et al., American Journal Physiol., vol. 262, (1992), pp. G616-G620.
Mark W. Gunion et al., American Journal Physiol., vol. 258, (1990), pp. G152-G157.
Hans Kristian Bakke et al., Life Sciences, vol. 45, (1989), pp. 907-916.
H. Jurgen Lenz et al., Gastroenterology, vol. 95, (1988), pp. 1510-1517.
Michael J. Ford et al., Gastroenterology, vol. 109, (1995), pp. 1772-1780.
T. Lembo et al., Neurogastroenterol. Mot., vol. 8, (1996), pp. 9-18.
S. Fukudo et al., Gut., vol. 42, (1998), pp. 845-849.
Akio Morimoto et al., Journal of Physiology, vol. 460, (1993), pp. 221-229.
Katia Karalis et al., Science, vol. 254, (Oct. 18, 1991), pp. 421-423.
Leslie J. Crofford et al., The Journal of Clinical Investigation, Inc., vol. 90, (Dec. 1992), pp. 2555-2564.
Leslie J. Crofford et al, The Journal of Immunology, vol. 151, No. 3, (Aug. 1, 1993), pp. 1587-1596.
Theoharis C. Theoharides et al., Endocrinology, vol. 139, No. 1, (1998), pp. 403-413.
Leena K. Singh et al., The Journal of Pharmacology and Experimental Therapeutics, vol. 288, No. 3, (1999), pp. 1349-1356.
Chrisoula D. Scopa et al., American Journal of Pathology, vol. 145, No. 5, (Nov. 1994), pp. 1159-1167.
Sebastian Poliak et al., The Journal of Immunology, vol. 158, (1997), pp. 5751-5756.
Yoshio Murakami et al., Endocrine Journal, vol. 44, No. 4, (1997), pp. 627-629.
Vijendra K. Singh, Journal of Neuroimmunology, vol. 23, (1989), pp. 257-262.
Vijendra K. Singh, Neuroscience Letters, vol. 120, (1990), pp. 151-154.
Rajeev Jain et al., Endocrinology, vol. 128, No. 3, (1991), pp. 1329-1336.
Gerd Bohmer et al., European Journal of Pharmacology, vol. 182, (1990), pp. 405-411.
M. Nink et al., Acta Endocrinologica, vol. 127, (1992), pp. 200-204.
Jean Rivier et al., Science, vol. 224, (May 25, 1984), pp
Hibi Shigeki
Hirakawa Tetsuya
Hoshino Yorihisa
Kikuchi Kouichi
Shibata Hisashi
Berch Mark L.
Birch & Stewart Kolasch & Birch, LLP
Eisai Co. Ltd.
Habte Kahsay
LandOfFree
Fused heterotricyclic compounds, process for preparing the... does not yet have a rating. At this time, there are no reviews or comments for this patent.
If you have personal experience with Fused heterotricyclic compounds, process for preparing the..., we encourage you to share that experience with our LandOfFree.com community. Your opinion is very important and Fused heterotricyclic compounds, process for preparing the... will most certainly appreciate the feedback.
Profile ID: LFUS-PAI-O-3479564